In the early hours of June 3, 2026 (Beijing time), longevity biotechnology startup NewLimit announced the completion of a $435 million Series C funding round. The round was led by Peter Thiel's Founders Fund, with continued participation from existing backers Abstract Ventures, Kleiner Perkins, NFDG, Eli Lilly Ventures, and Valor Equity Partners, while new investors Thrive Capital, Greenoaks, and Quiet Capital also joined. According to The Wall Street Journal, the round valued the company at $3.1 billion, more than tripling its valuation from just a year ago.
In its funding announcement, NewLimit revealed that following breakthrough research results, the company is moving longevity medicine into human clinical trials. Its first drug, targeting alcohol-related liver disease, is expected to enter clinical testing next year. The company stressed that “by reprogramming cell age, humanity can achieve longer healthspan, and we are now closer than ever to delaying or even reversing aging.”
Coinbase Co-Founder’s Leap into Longevity
NewLimit’s story is intertwined with a familiar name from the crypto world — Coinbase founder and CEO Brian Armstrong. In 2021, Armstrong joined forces with former GV partner and bioengineer Blake Byers and stem cell biologist Jacob Kimmel to personally invest $110 million to launch the company in South San Francisco. Prior to this round, NewLimit had already completed three rounds of financing, attracting top venture capital and strategic industry funds.
The company’s core mission is to develop drugs that extend healthy lifespan. As its official description explains, cellular function gradually declines with age, making people more susceptible to disease. Aging was once thought to be inevitable, but emerging science shows that the aging process can be reversed at the cellular level. NewLimit is building on these findings to create the first therapies that restore youthful function to aged cells.
The Science: Yamanaka Factors and Cellular Reprogramming
The scientific foundation for reversing cell age dates back to a Nobel Prize-winning discovery in 2006. Japanese scientist Shinya Yamanaka found that activating just a few specific transcription factors could reprogram adult cells back into a youthful, embryonic stem cell-like state. These were later called “Yamanaka Factors,” a breakthrough that earned him the 2012 Nobel Prize in Physiology or Medicine.
This discovery proved for the first time that cellular age is not irreversible, and NewLimit builds directly on that insight. “Our medicines aim to reverse the epigenome of cells to a younger state by activating specific transcription factor genes,” the company explains. “While we know such reversal is possible, the exact combination of transcription factors needed to restore youthful function in different cell types remains unknown. Identifying these effective gene payloads is the central challenge of our work.”
Liver Disease as an Accelerated Aging Model
NewLimit’s strategy is to first tackle a specific disease, secure drug approval, and then expand into broader anti-aging applications. Alcohol-related liver disease was chosen as the inaugural clinical indication. Co-founder and CEO Jacob Kimmel described liver disease as a form of “accelerated aging,” a more aggressive, faster version of the same biological decline that everyone eventually faces.
This focus not only simplifies the clinical trial pathway but also provides a faster route to demonstrating the safety and efficacy of cellular reprogramming in humans, paving the way for a much wider range of longevity-related indications.
The Billionaire Longevity Race
NewLimit is far from the only company chasing the dream of radical life extension. In 2022, Sam Altman invested $180 million into Retro Biosciences, which is developing drugs to rejuvenate aging cells and recently disclosed a valuation of $1.8 billion. That same year, Altos Labs launched with $3 billion in backing, reportedly including funds from Jeff Bezos, and has since roughly doubled that total.
From Peter Thiel to Sam Altman to Jeff Bezos, the heavy hitters pouring billions into longevity share a common driver: when wealth and power peak, time becomes the ultimate scarce resource. Thiel has openly voiced his deep disdain for death, calling it the greatest enemy of humanity. For these titans, betting vast fortunes on delaying — or even reversing — aging is not just ambition, but an assault on the final frontier of human limitation.